Abstract:Pituitary tumors are very complex and heterogeneous and have a very wide range of proliferative and aggressive behaviors, and how to define and classify these tumors remains controversial. This review summarizes the epidemiology and progress in the classification and definition of pituitary tumors, as well as controversial issues. Based on the results of radiologic and autopsy studies, the prevalence of pituitary tumors has recently increased significantly. However, the majority of pituitary tumors are incidentally discovered and asymptomatic, and such tumors are called pituitary incidentalomas. Most of these incidentalomas do not induce symptoms, remain stable in size, and do not need treatment. The recent revised classification strategies mainly depend on immunohistochemistry (IHC) to detect pituitary hormones and pituitary transcription factors; therefore, the accuracy of diagnosing pituitary tumors has improved. Although new classification strategies and definitions for pituitary tumors have been presented, there are still some controversies. The term pituitary neuroendocrine tumor (PitNET) was proposed by the International Pituitary Pathology Club, and this terminology can encompass the unpredictable malignant behavior seen in the subset of aggressive pituitary adenomas (PAs). However, some endocrinologists who oppose this change in terminology have argued that the use of tumor in the terminology is misleading, as it gives PAs a harmful connotation when the majority are not aggressive. Such terminology may add new ambiguity to the origin of PAs and unnecessary anxiety and frustration for the majority of patients with benign PAs. The classification of aggressive PAs mainly relies on subjective judgment of clinical behavior and lacks objective biomarkers and unified diagnostic criteria. However, the term "refractory" could more accurately represent the characteristics of these tumors, including their clinical behaviors, radiological features, and pathologic characteristics. Moreover, the diagnostic criteria for refractory PAs are stricter, more objective, and more accurate than those for aggressive PAs. Early identification of patients with these tumors through recognition and increased awareness of the definition of refractory PAs will encourage the early use of aggressive therapeutic strategies.

Metabolic Reprogramming Drives Pituitary Tumor Growth through Epigenetic Regulation of TERT

Argininosuccinate Lyase Drives Activation of Mutant TERT Promoter in Glioblastomas

Metabolic Abnormalities in Pituitary Adenoma Patients: A Novel Therapeutic Target and Prognostic Factor

Whole Genome Sequencing and single-cell transcriptomics identify KMT2D as a potential new driver for pituitary adenomas

Epigenetic reprogramming induced by Acetyl-CoA and SAM depletion is an evolutionarily-ancient path to malignant growth

Glycolysis, the sweet appetite of the tumor microenvironment

Exploring the mystery of tumor metabolism: Warburg effect and mitochondrial metabolism fighting side by side

Metabolic reprogramming and epigenetic modifications on the path to cancer

Numb/Parkin-directed Mitochondrial Fitness Governs Cancer Cell Fate Via Metabolic Regulation of Histone Lactylation

Single Cell Metabolic Landscape of Pituitary Neuroendocrine Tumor Subgroups and Lineages

Reprogramming Metabolism by Histone Methyltransferase NSD2 Drives Endocrine Resistance Via Coordinated Activation of Pentose Phosphate Pathway Enzymes.

Epigenomic Reprogramming During Pancreatic Cancer Progression Links Anabolic Glucose Metabolism to Distant Metastasis

Tumor Metabolic Reprogramming in Lung Cancer Progression.

Metabolic reprogramming in tumors: Contributions of the tumor microenvironment

[Metabolic reprogramming in cancer: the art of balance].

Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target

Drp1-Mediated Mitochondrial Metabolic Dysfunction Inhibits the Tumor Growth of Pituitary Adenomas

A metabolic-epigenetic mechanism directs cell fate and therapeutic sensitivity in breast cancer

How To Classify And Define Pituitary Tumors: Recent Advances And Current Controversies

Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment

Epigenetic Regulation of the Warburg Effect by H2B Monoubiquitination